This PDF is the current document as it appeared on Public Inspection on 03/30/2012 at 08:45 am.
Final rule; correction.
In the Federal Register of March 9, 2012 (76 FR 14272), the Food and Drug Administration (FDA) classified norovirus serological reagents into class II (special controls) because special controls, in addition to general controls, will provide a reasonable assurance of safety and effectiveness of these devices. The document published with inadvertent errors in the Analysis of Impacts section. This document corrects those errors.
Effective April 9, 2012.
FOR FURTHER INFORMATION CONTACT:
Steven Gitterman, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 5518, Silver Spring, MD 20993-0002, 301-796-6694.
In FR Doc. 2012-5675 appearing on page 14272 in the Federal Register of Friday, March 9, 2012, the following corrections are made:
1. On page 14274, in the first column, in section VI. Analysis of Impacts, in the first paragraph, in the last sentence, correct the phrase “proposed rule” to read “final rule”, and in the second paragraph, in the last sentence, correct the phrase “proposes to certify” to read “certifies”.
2. On page 14274, in the second column, in the first full sentence, correct the phrase “proposed rule” to read “final rule”.
Dated: March 27, 2012.
Assistant Commissioner for Policy.
[FR Doc. 2012-7757 Filed 3-30-12; 8:45 am]
BILLING CODE 4160-01-P